Table 4.
MA use | Heavy MA Use (N=31) | Some MA Use (N=142) | ||||
---|---|---|---|---|---|---|
Trimester | ||||||
First | Second | Third | First | Second | Third | |
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Daily | 18 (58.1%) | 14 (45.2%) | 4 (12.9%) | 13 (9.2%) | 1 (0.7%) | 1 (0.7%) |
3-6 days/wk. | 12 (38.7%) | 15 (48.4%) | 10 (32.3%) | 36 (25.4%) | 9 (6.3%) | 1 (0.7%) |
1-2 days/wk. | 0 (0%) | 2 (6.5%) | 2 (6.5%) | 24 (16.9%) | 15 (10.6%) | 8 (5.6%) |
1-3 days/mo. | 0 (0%) | 0 (0%) | 1 (3.2%) | 16 (11.3%) | 17 (12.0%) | 13 (9.2%) |
1-2 days/3 mos. | 0 (0%) | 0 (0%) | 2 (6.5%) | 24 (16.9%) | 21 (14.8%) | 28 (19.7%) |
Not at all | 1 (3.2%) b | 0 (0%) | 11 (35.5%) | 27 (19.0%) | 79 (55.6%) | 91 (64.1%) |
Days/week (mean, SD) | 5.87 (1.70) | 5.15 (1.89) | 2.59 (2.69) | 1.98 (2.22) | 0.50 (1.07) | 0.21 (0.73) |
6 of the 179 MA users in this study were identified as exposed by toxicology only
1 case classified as a heavy user who abstained in the 1st trimester: 2nd trimester use-3.5 days/wk; 3rd trimester use-5.5 days/wk